Trial Profile
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of 150 mg Dabigatran Etexilate p.o. in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function in a Monocentric, Open, Parallel-group Design
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Liver disorders
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 26 Jun 2014 New trial record